Liquid biopsy for lung cancer screening: Usefulness of circulating tumor cells and other circulating blood biomarkers.
blood test
early detection
liquid biopsy
lung carcinoma
Journal
Cancer cytopathology
ISSN: 1934-6638
Titre abrégé: Cancer Cytopathol
Pays: United States
ID NLM: 101499453
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
revised:
04
09
2020
received:
24
08
2020
accepted:
08
09
2020
pubmed:
3
10
2020
medline:
5
10
2021
entrez:
2
10
2020
Statut:
ppublish
Résumé
Screening for lung cancer has become a reality in certain countries, most notably the United States, but its implementation currently is under discussion and not established in many nations, including France. Screening for lung cancer currently is proposed using a low-dose computed tomography scanner. However, this approach lacks sensitivity and specificity, and could be improved when combined with a blood test (so-called "liquid biopsy"). Such tests attempt to detect biomarker (s) of early cancer development. Thus, numerous studies performed within the last few years have examined different blood components including circulating tumor cells and free DNA and other circulating elements such as microRNAs, exosomes, antibodies, and proteins. Recent studies have highlighted the value of seeking a signature for the methylation of circulating free DNA, which can be specific for certain solid tumors, including lung carcinoma. The current study describes some recent developments in the use of liquid biopsies for the detection of early-stage lung cancers, even those that are not yet visible using a low-dose computed tomography scanner.
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
341-346Informations de copyright
© 2020 American Cancer Society.
Références
National Lung Screening Trial Research Team, Church TR, Black WC, et al. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013;368:1980-1991.
Ostrowski M, Marjanski T, Rzyman W. Low-dose computed tomography screening reduces lung cancer mortality. Adv Med Sci. 2018;63:230-236.
de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2020;382:503-513.
Balata H, Evison M, Sharman A, Crosbie P, Booton R. CT screening for lung cancer: are we ready to implement in Europe? Lung Cancer. 2019;134:25-33.
Calabrese F, Lunardi F, Pezzuto F, et al. Are there new biomarkers in tissue and liquid biopsies for the early detection of non-small cell lung cancer? J Clin Med. 2019;8:414.
Seijo LM, Peled N, Ajona D, et al. Biomarkers in lung cancer screening: achievements, promises, and challenges. J Thorac Oncol. 2019;14:343-357.
Heidrich I, Ackar L, Mohammadi PM, Pantel K. Liquid biopsies: potential and challenges. Int J Cancer. Published online July 19, 2020. doi:10.1002/ijc.33217
Pantel K. Blood tests for early detection of lung cancer: challenges and promises. Lancet Respir Med. 2020;8:654-656.
The Lancet Oncology. Cancer detection: the quest for a single liquid biopsy for all. Lancet Oncol. 2020;21:733.
Hofman V, Ilie MI, Long E, et al. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the CellSearch Assay™ and the isolation by size of epithelial tumor cell method. Int J Cancer. 2011;129:1651-1660.
Hofman V, Bonnetaud C, Ilie MI, et al. Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker. Clin Cancer Res. 2011;17:827-835.
Chemi F, Rothwell DG, McGranahan N, et al. Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse. Nat Med. 2019;25:1534-1539.
Hofman P. Liquid biopsy for early detection of lung cancer. Curr Opin Oncol. 2017;29:73-78.
Desitter I, Guerrouahen BS, Benali-Furet N, et al. A new device for rapid isolation by size and characterization of rare circulating tumor cells. Anticancer Res. 2011;31:427-441.
Vona G, Sabile A, Louha M, et al. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulating tumor cells. Am J Pathol. 2000;156:57-63.
Massard C, Borget I, Farace F, et al. RECIST response and variation of circulating tumour cells in phase 1 trials: a prospective multicentric study. Eur J Cancer. 2017;83:185-193.
Ilie M, Hofman V, Long-Mira E, et al. “Sentinel” circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease. PLoS One. 2014;9:e111597.
Leroy S, Benzaquen J, Mazzetta A, et al. Circulating tumour cells as a potential screening tool for lung cancer (the AIR study): protocol of a prospective multicentre cohort study in France. BMJ Open. 2017;7:e018884.
Marquette CH, Boutros J, Benzaquen J, et al. Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort study. Lancet Respir Med. 2020;8:709-716.
Manjunath Y, Upparahalli SV, Suvilesh KN, et al. Circulating tumor cell clusters are a potential biomarker for detection of non-small cell lung cancer. Lung Cancer. 2019;134:147-150.
Hofman V, Long E, Ilie M, et al. Morphological analysis of circulating tumour cells in patients undergoing surgery for non-small cell lung carcinoma using the isolation by size of epithelial tumour cell (ISET) method. Cytopathology. 2012;23:30-38.
Hofman V, Ilie M, Long E, et al. Detection of circulating tumor cells from lung cancer patients in the era of targeted therapy: promises, drawbacks and pitfalls. Curr Mol Med. 2014;14:440-456.
Adams DL, Martin SS, Alpaugh RK, et al. Circulating giant macrophages as a potential biomarker of solid tumors. Proc Natl Acad Sci U S A. 2014;111:3514-3519.
Ball ED. Introduction: workshop summary of the CD15 monoclonal antibody panel from the Fifth International Workshop on Leukocyte Antigens. Eur J Morphol. 1995;33:95-100.
Hofman VJ, Ilie M, Hofman PM. Detection and characterization of circulating tumor cells in lung cancer: why and how? Cancer Cytopathol. 2016;124:380-387.
Katz RL, Zaidi TM, Pujara D, et al. Identification of circulating tumor cells using 4-color fluorescence in situ hybridization: validation of a noninvasive aid for ruling out lung cancer in patients with low-dose computed tomography-detected lung nodules. Cancer Cytopathol. 2020;128:553-562.
Chen X, Gole J, Gore A, et al. Non-invasive early detection of cancer four years before conventional diagnosis using a blood test. Nat Commun. 2020;11:3475.
Constancio V, Nunes SP, Henrique R, Jeronimo C. DNA methylation-based testing in liquid biopsies as detection and prognostic biomarkers for the four major cancer types. Cells. 2020;9:624.
Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31:745-756.
Yang Z, Qi W, Sun L, Zhou H, Zhou B, Hu Y. DNA methylation analysis of selected genes for the detection of early-stage lung cancer using circulating cell-free DNA. Adv Clin Exp Med. 2019;28:355-360.
Razavi P, Li BT, Brown DN, et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat Med. 2019;25:1928-1937.
Cristiano S, Leal A, Phallen J, et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature. 2019;570:385-389.
LeBleu VS, Kalluri R. Exosomes as a multicomponent biomarker platform in cancer. Trends Cancer. 2020;6:767-774.
Sohel MMH. Circulating microRNAs as biomarkers in cancer diagnosis. Life Sci. 2020;248:117473.
Tang Z, Li D, Hou S, Zhu X. The cancer exosomes: clinical implications, applications and challenges. Int J Cancer. 2020;146:2946-2959.
Drula R, Ott LF, Berindan-Neagoe I, Pantel K, Calin GA. MicroRNAs from liquid biopsy derived extracellular vesicles: recent advances in detection and characterization methods. Cancers (Basel). 2020;12:E2009.
Srivastava S, Hanash S. Pan-cancer early detection: hype or hope? Cancer Cell. 2020;38:23-24.
Benzaquen J, Boutros J, Marquette C, Delingette H, Hofman P. Lung cancer screening, towards a multidimensional approach: why and how? Cancers (Basel). 2019;11:212.
Lennon AM, Buchanan AH, Kinde I, et al. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science. 2020;369:eabb9601.